Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 1 of 8 PageID #: 544
`
`Exhibit C
`
`

`

`Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 2 of 8 PageID #: 545
`
`From:
`To:
`
`Cc:
`Subject:
`Date:
`Attachments:
`
`Importance:
`
`Dov P. Grossman
`Todd S Werner; Jennell C Bilek; Regorafenib; David Fry; Scott, Ian; Kenneth L. Dorsney; Shelleaha L Jonas;
`Kouyoumdjian, Philip Y.; Karen Keller
`Jessica B. Rydstrom; Bowers, Seth; Picozzi, Ben; Derek J. Fahnestock; Anthony D. Raucci
`RE: Draft Claim Chart
`Friday, May 18, 2018 3:47:38 PM
`image007.png
`image003.emz
`image002.png
`Low
`
`Todd – we believe that we have answered your question. (By contrast, you still have not provided us
`with an explanation as to why the definition in the specification should be altered as you have
`proposed.) While you may believe that this is a question of whether certain portions of your
`construction are “accurate” versus “inaccurate,” we see it differently—as I explained in my email, we
`disagree with your construction.
`
`Regards,
`Dov
`
`From: Todd S Werner [mailto:TWerner@carlsoncaspers.com]
`Sent: Thursday, May 17, 2018 3:20 PM
`To: Grossman, Dov <DGrossman@wc.com>; Jennell C Bilek <JBilek@carlsoncaspers.com>;
`Regorafenib <Regorafenib@carlsoncaspers.com>; David Fry <dfry@shawkeller.com>; Scott, Ian
`<iscott@taftlaw.com>; Kenneth L. Dorsney <kdorsney@morrisjames.com>; Shelleaha L Jonas
`<SJonas@carlsoncaspers.com>; Kouyoumdjian, Philip Y. <pkouyoumdjian@taftlaw.com>; Karen
`Keller <kkeller@shawkeller.com>
`Cc: Rydstrom, Jessica <JRydstrom@wc.com>; Bowers, Seth <SBowers@wc.com>; Picozzi, Ben
`<BPicozzi@wc.com>; Derek J. Fahnestock <dfahnestock@mnat.com>; Anthony D. Raucci
`<araucci@mnat.com>
`Subject: RE: Draft Claim Chart
`
`Dov:
`
`Our question remains unanswered. Does Bayer believe that Defendants’ proposed construction is
`inaccurate, e.g. too broad or too narrow? If so, please let us know those aspects of Defendants’
`proposed construction that Bayer believes improperly expand or limit the scope of the disputed
`claim term “effective amount.”
`
`Best regards,
`
`
`Todd S. Werner | Attorney
`Direct: 612.436.9655
`Main: 612.436.9600
`twerner@carlsoncaspers.com
`
`
`
`carlsoncaspers.com
`
`This message may contain privileged or confidential information. If you are not the addressee, note that any disclosure,
`
`

`

`Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 3 of 8 PageID #: 546
`
`copying, distribution or use of its contents is prohibited. If you have received this message in error, please destroy it and
`notify us immediately at 612.436.9600.
`
`
`
`
`From: Grossman, Dov [mailto:DGrossman@wc.com]
`Sent: Thursday, May 17, 2018 12:56 PM
`To: Todd S Werner; Jennell C Bilek; Regorafenib; David Fry; Scott, Ian; Kenneth L. Dorsney; Shelleaha L
`Jonas; Kouyoumdjian, Philip Y.; Karen Keller
`Cc: Jessica B. Rydstrom; Bowers, Seth; Picozzi, Ben; Derek J. Fahnestock; Anthony D. Raucci
`Subject: RE: Draft Claim Chart
`
`Todd,
`
`We disagree with a number of the statements in your e-mail. Bayer has not "refuse[d] to tell" Teva
`what Bayer’s position is regarding "effective amount." We have told you that our construction is
`based on the definition of "effective amount" in the specification. Teva has proposed a different
`construction which is not that definition and has offered no explanation as to why the definition
`from the specification should be altered. We therefore disagree with Teva's construction.
`
`Additionally, we note that Bayer has not had Teva's "supporting intrinsic evidence" "for weeks," as
`you suggest. The parties just yesterday agreed to a schedule for the exchange of intrinsic evidence.
`(Indeed, Bayer had proposed an earlier deadline for the initial exchange, which Teva rejected.)
`
`We agree that the parties should engage in a meaningful confer about their proposed construction,
`and, accordingly, have provided the basis for our construction, which is at least as much information
`as Teva has provided about its own construction. We are always willing to meet and confer, but a
`proper meet and confer must be a mutual exchange of information about the parties' respective
`positions, not a unilateral demand from Teva for Bayer to identify which parts of Teva's construction
`are "accurate" versus "inaccurate." This is particularly so when Bayer has already explained that it is
`relying on a definition from the specification.
`
`Regards,
`Dov
`
`From: Todd S Werner [mailto:TWerner@carlsoncaspers.com]
`Sent: Wednesday, May 16, 2018 8:03 PM
`To: Grossman, Dov <DGrossman@wc.com>; Jennell C Bilek <JBilek@carlsoncaspers.com>;
`Regorafenib <Regorafenib@carlsoncaspers.com>; David Fry <dfry@shawkeller.com>; Scott, Ian
`<iscott@taftlaw.com>; Kenneth L. Dorsney <kdorsney@morrisjames.com>; Shelleaha L Jonas
`<SJonas@carlsoncaspers.com>; Kouyoumdjian, Philip Y. <pkouyoumdjian@taftlaw.com>; Karen
`Keller <kkeller@shawkeller.com>
`Cc: Rydstrom, Jessica <JRydstrom@wc.com>; Bowers, Seth <SBowers@wc.com>; Picozzi, Ben
`<BPicozzi@wc.com>; Derek J. Fahnestock <dfahnestock@mnat.com>; Anthony D. Raucci
`<araucci@mnat.com>
`Subject: Re: Draft Claim Chart
`
`

`

`Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 4 of 8 PageID #: 547
`
`
`Dov:
`
`The Court expects the parties to meaningful confer about their proposed
`constructions. Plaintiffs have had our proposed construction for weeks, as well as
`supporting intrinsic evidence. Despite this, Plaintiffs have yet to express any reason
`why they disagree with that construction. Do plaintiffs simply believe it is
`unnecessary? Or do they believe it is affirmatively wrong, and if so, why? We have
`been asking for that information for weeks to no avail.
`
`It is not possible for us to address Plaintiffs' position if Plaintiffs refuse to tell us what it
`is.
`If you want to keep Defendants in the dark, I suppose that is your call. Of course,
`we will be sure to let the Court know the reason we haven't addressed Plaintiffs'
`position in our opening brief.
`
`Best regards,
`
`Todd Werner
`
`-------- Original message --------
`From: "Grossman, Dov" <DGrossman@wc.com>
`Date: 5/16/18 4:51 PM (GMT-06:00)
`To: Jennell C Bilek <JBilek@carlsoncaspers.com>, Regorafenib
`<Regorafenib@carlsoncaspers.com>, David Fry <dfry@shawkeller.com>, "Scott, Ian"
`<iscott@taftlaw.com>, "Kenneth L. Dorsney" <kdorsney@morrisjames.com>, Shelleaha L
`Jonas <SJonas@carlsoncaspers.com>, "Kouyoumdjian, Philip Y."
`<pkouyoumdjian@taftlaw.com>, Karen Keller <kkeller@shawkeller.com>
`Cc: "Jessica B. Rydstrom" <jrydstrom@wc.com>, "Bowers, Seth" <SBowers@wc.com>,
`"Picozzi, Ben" <BPicozzi@wc.com>, "Derek J. Fahnestock" <dfahnestock@mnat.com>,
`"Anthony D. Raucci" <araucci@mnat.com>
`Subject: RE: Draft Claim Chart
`
`Jennell,
`
`We are fine with 2 pm ET on May 21 for the initial exchange of intrinsic evidence.
`
`With regard to “effective amount,” we fail to understand the basis for your request. We disagree
`with Teva’s construction and have proposed a competing construction. The issue is not for Bayer to
`“identify which portion(s) of Teva’s proposed construction for ‘effective amount’ is inaccurate.”
`Rather, the issue for Teva is to justify its proposed construction, which we do not believe you have
`done.
`
`Regards,
`Dov
`
`From: Jennell C Bilek [mailto:JBilek@carlsoncaspers.com]
`Sent: Wednesday, May 16, 2018 9:58 AM
`
`

`

`Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 5 of 8 PageID #: 548
`
`To: Grossman, Dov <DGrossman@wc.com>; Regorafenib <Regorafenib@carlsoncaspers.com>; David
`Fry <dfry@shawkeller.com>; Scott, Ian <iscott@taftlaw.com>; Kenneth L. Dorsney
`<kdorsney@morrisjames.com>; Shelleaha L Jonas <SJonas@carlsoncaspers.com>; Kouyoumdjian,
`Philip Y. <pkouyoumdjian@taftlaw.com>; Karen Keller <kkeller@shawkeller.com>
`Cc: Rydstrom, Jessica <JRydstrom@wc.com>; Bowers, Seth <SBowers@wc.com>; Picozzi, Ben
`<BPicozzi@wc.com>; Derek J. Fahnestock <dfahnestock@mnat.com>; Anthony D. Raucci
`<araucci@mnat.com>
`Subject: RE: Draft Claim Chart
`
`Dov,
`
`Defendants would prefer May 21 instead of May 18 for the initial exchange. The schedule below is
`otherwise fine. Please confirm May 21 is acceptable. In addition, as requested in our May 1 letter
`and my email of May 8, please identify which portion(s) of Teva’s proposed construction for
`“effective amount” is inaccurate.
`
`Regards, Jennell
`
`
`
`Jennell C. Bilek, Ph.D.
`direct 612.436.9648
`main 612.436.9600
`jbilek@carlsoncaspers.com
`
`carlsoncaspers.com
`
`
`
`This message may contain privileged or confidential information. If you are not the addressee, note that any disclosure,
`copying, distribution or use of its contents is prohibited. If you have received this message in error, please destroy it and
`notify us immediately at 612.436.9600.
`
`From: Grossman, Dov [mailto:DGrossman@wc.com]
`Sent: Tuesday, May 15, 2018 3:49 PM
`To: Jennell C Bilek; Regorafenib; David Fry; Scott, Ian; Kenneth L. Dorsney; Shelleaha L Jonas;
`Kouyoumdjian, Philip Y.; Karen Keller
`Cc: Jessica B. Rydstrom; Bowers, Seth; Picozzi, Ben; Derek J. Fahnestock; Anthony D. Raucci
`Subject: RE: Draft Claim Chart
`
`All,
`
`Attached is an updated draft of the joint claim chart, with Bayer’s proposed changes in redline.
`
`With regard to the exchange of intrinsic evidence, we suggest the following schedule:
`
`May 18 at 2 pm ET: initial exchange of citations to intrinsic evidence
`May 22 at 2 pm ET: supplement citations to intrinsic evidence
`May 23 at 3 pm ET: finalize joint claim chart
`
`Please let us know if this is acceptable.
`
`
`

`

`Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 6 of 8 PageID #: 549
`
`Regards,
`Dov
`
`Dov P. Grossman
`Williams & Connolly LLP
`725 Twelfth St., N.W., Washington, DC 20005
`(P) 202-434-5812 | (F) 202-480-8268
`dgrossman@wc.com | www.wc.com/dgrossman
`
`
`
`From: Jennell C Bilek [mailto:JBilek@carlsoncaspers.com]
`Sent: Tuesday, May 08, 2018 4:18 PM
`To: Grossman, Dov <DGrossman@wc.com>; Regorafenib <Regorafenib@carlsoncaspers.com>; David
`Fry <dfry@shawkeller.com>; Scott, Ian <iscott@taftlaw.com>; Kenneth L. Dorsney
`<kdorsney@morrisjames.com>; Shelleaha L Jonas <SJonas@carlsoncaspers.com>; Kouyoumdjian,
`Philip Y. <pkouyoumdjian@taftlaw.com>; Karen Keller <kkeller@shawkeller.com>
`Cc: Rydstrom, Jessica <JRydstrom@wc.com>; Bowers, Seth <SBowers@wc.com>; Picozzi, Ben
`<BPicozzi@wc.com>; Derek J. Fahnestock <dfahnestock@mnat.com>; Anthony D. Raucci
`<araucci@mnat.com>
`Subject: RE: Draft Claim Chart
`
`Counsel,
`
` I
`
` write on behalf of the Defendants concerning the Joint Claim Construction Chart and email
`received today from Plaintiffs. Defendants incorporate two revisions to the Chart in the attached.
`First, unless requested to do so by the Court, Defendants will not brief indefiniteness as part of claim
`construction for the terms proposed for construction in the attached. Second, Defendants added
`the claims to be construed for the 107 patent.
`
`In terms of Plaintiffs request for an extension, Defendants do not believe another extension is
`warranted, but out of professional courtesy, will not oppose a one-week extension. Please provide
`the schedule you refer to below regarding exchange of intrinsic evidence. In addition, as requested
`in our May 1 letter, please confirm which portion(s) of Teva’s proposed construction for “effective
`amount” is inaccurate.
`
`
`Regards, Jennell
`
`
`
`
`Jennell C. Bilek, Ph.D.
`direct 612.436.9648
`main 612.436.9600
`jbilek@carlsoncaspers.com
`
`

`

`Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 7 of 8 PageID #: 550
`
`carlsoncaspers.com
`
`
`
`This message may contain privileged or confidential information. If you are not the addressee, note that any disclosure,
`copying, distribution or use of its contents is prohibited. If you have received this message in error, please destroy it and
`notify us immediately at 612.436.9600.
`
`From: Grossman, Dov [mailto:DGrossman@wc.com]
`Sent: Tuesday, May 8, 2018 7:02 AM
`To: Regorafenib; David Fry; Scott, Ian; Kenneth L. Dorsney; Shelleaha L Jonas; Jennell C Bilek;
`Kouyoumdjian, Philip Y.
`Cc: Jessica B. Rydstrom; Bowers, Seth; Picozzi, Ben; Derek J. Fahnestock; Anthony D. Raucci
`Subject: Draft Claim Chart
`
`All,
`
`Please find attached a draft joint claim chart, which sets forth Bayer’s proposed constructions
`regarding the terms/phrases proposed for construction for the ’124 patent. Bayer reserves the right
`to modify these proposed constructions as the claim construction process continues.
`
`Per Defendants’ May 1 letter that Defendants have withdrawn all terms for construction for the ’553
`patent, no terms have been included for that patent. Similarly, since Bayer is no longer asserting
`claim 4 of the ’834 patent, no terms have been included for that patent.
`
`With regard to the ’107 patent, we are still considering Defendants’ newly proposed term for
`construction (“in an amount equal to or less than 0.05%”) as well as Defendants’ proposed
`construction. Given the timing of Defendants’ disclosure, in order to allow Bayer to fully consider
`this issue, we propose that the parties stipulate to extend the deadline for submission of the joint
`claim chart to May 29. Please let us know whether Defendants agree.
`
`Finally, for clarity, Defendants’ May 1 letter does not accurately reflect Bayer’s position regarding
`citations to the intrinsic record; rather, we proposed that the parties set a schedule for such an
`exchange. To that end, we will propose a schedule once the parties reach agreement on a revised
`deadline for submission of the joint claim chart.
`
`Regards,
`Dov
`
`Dov P. Grossman
`Williams & Connolly LLP
`725 Twelfth St., N.W., Washington, DC 20005
`(P) 202-434-5812 | (F) 202-480-8268
`dgrossman@wc.com | www.wc.com/dgrossman
`
`
`This message and any attachments are intended only for the addressee and may contain information that is
`privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or
`
`

`

`Case 1:16-cv-01221-LPS Document 58-3 Filed 06/13/18 Page 8 of 8 PageID #: 551
`
`disclose the contents of the message and any attachments. Instead, please delete the message and any attachments
`and notify the sender immediately. Thank you.
`
`